| A545 |
Ociperlimab
Featured
|
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer. |
|
| DC67103 |
Nerandomilast dihydrate
Featured
|
Nerandomilast (BI 1015550) dihydrate is an orally active inhibitor of PDE4B with an IC50 value of 7.2 nM. Nerandomilast (dihydrate) has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD). |
|
| A546 |
Etigilimab
Featured
|
Etigilimab (OMP-313M32), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (CD155; poliovirus receptor) and inhibits downstream signalling with target cell killing. |
|
| A547 |
Domvanalimab
Featured
|
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used in research of cancer. |
|
| A548 |
Cobolimab
Featured
|
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC). |
|
| A549 |
Sabatolimab
Featured
|
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells. |
|
| A550 |
Tomaralimab
Featured
|
Tomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS). |
|
| A551 |
Anti-TLR3/CD283 Antibody (CNTO5429)
Featured
|
|
|
| A552 |
U.Tokyo patent anti-TLR7
Featured
|
|
|
| A553 |
Beth Israel Patent Anti-TM4SF1
Featured
|
|
|
| A554 |
Bluefin patent anti-TMEFF1
Featured
|
|
|
| A555 |
Janssen patent anti-TMEFF2
Featured
|
|
|
| A556 |
Regeneron patent anti-TMPRSS2
Featured
|
|
|
| A557 |
Mapatumumab
Featured
|
Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer. |
|
| A558 |
Lexatumumab
Featured
|
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research. |
|
| A559 |
Drozitumab
Featured
|
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma. |
|
| A560 |
Benufutamab
Featured
|
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects. |
|
| A561 |
Conatumumab
Featured
|
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. . |
|
| A562 |
Tilogotamab
Featured
|
Tilogotamab (GEN-1029) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM). |
|
| A563 |
Enavatuzumab
Featured
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo . |
|
| A564 |
Ianalumab
Featured
|
Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM). |
|
| DC67104 |
DCP-LA(FR 236924)
Featured
|
DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis. |
|
| A565 |
Belantamab
Featured
|
Belantamab (GSK2857914) is a humanised IgG1 anti-BCMA (TNFRSF17) monoclonal antibody. Belantamab can be used in the synthesis of antibody-drug conjugate (ADC), Belantamab mafodotin. |
|
| A566 |
Ragifilimab
Featured
|
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research. |
|
| A567 |
Korea Natl.Cancer Ctr. patent anti-GITR
Featured
|
|
|
| A568 |
Abbvie patent anti-TNFRSF21
Featured
|
|
|
| DC67105 |
VCPIP1-IN-1
Featured
|
VCPIP1-IN-1 (Compound 001) is a VCPIP1 inhibitor, with an IC50 of 0.41 μM. |
|
| DC67106 |
BML-286 (Compound 3289-8625)
Featured
|
BML-286 (Compound 3289-8625) is a small molecule inhibitor of the PDZ domain of dishevelled (Dvl) with KD of 10.6 uM, competitively inhibits the Wnt signaling.
Compound 3289-8625 (3 uM) inhibits Wnt signaling, effectively reduces luciferase activity by about 2-fold 293 cell line stably transfected with a luciferase reporter.
Compound 3289-8625 is cell-permeable and 3289-8625 (10 uM) blocks Wnt signaling in Xenopus, inhibits Wnt pathway responses in culture and in vivo.
Compound 3289-8625 suppresses cell proliferation and reduces β-catenin level in prostate cancer PC-3 cells, decreases the levels of β-catenin in both cytosolic fraction and membrane fraction.
Compound 3289-8625 sensitized A2780/Taxol cells to paclitaxel. |
|
| DC67107 |
cmp2
Featured
|
cmp2 is a selective TRPC6 activator suitable for treatment of synaptic deficiency in Alzheimer’s disease hippocampal neurons,Cmp2 selectively activates TRPC6 but not structurally related TRPC3 and TRPC7. Cmp2 exhibits synaptoprotective properties in culture and slices and penetrates the BBB. In vivo study indicated cmp2 (10 mg/kg I.P.) reversed deficits in synaptic plasticity in the 5xFAD mice. |
|
| A569 |
Revdofilimab
Featured
|
Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells. |
|
